[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-stimulation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,75,101,124,150,178,202,235,265,288,315,343],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100630465","effects-of-the-stimulation-site-of-tsms-with-tms-on-functional-mobility-in-individuals-with-parkinsons-disease-100630465",false,"NCT07488026","Effects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease","Effects of the Stimulation Site of Trans-spinal Magnetic Stimulation Combined With Transcranial Magnetic Stimulation on Functional Mobility in Individuals With Parkinson's Disease","Inclusion Criteria: (i) a clinical diagnosis of Parkinson's disease confirmed by a neurologist; (ii) stable dopaminergic pharmacological treatment for at least three months; (iii) age 40 years or older; (iv) disease stage between 2.5 and 3 on the modified Hoehn and Yahr scale; (v) (v) gait impairment, defined as the occurrence of at least one freezing of gait episode per week.\n\n\\-\n\nExclusion Criteria:\n\n(i) other neurological disorders, orthostatic hypotension, vestibular, musculoskeletal, or visual impairments that could compromise performance on the proposed assessments; (ii) other osteomuscular conditions affecting the lower limbs that interfere with mobility and functional performance; (iii) a Montreal Cognitive Assessment (MoCA) score lower than 21 points; (iv) prior surgical procedures for Parkinson's disease; or (v) contraindications to magnetic stimulation techniques, including a history of seizures or the presence of metallic implants in the neck or spinal region.","ALL","40 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized clinical trial aims to compare the effects of two different trans-spinal magnetic stimulation (tsMS) application sites, cervical versus thoracic, when combined with repetitive transcranial magnetic stimulation (rTMS), on functional mobility in individuals with Parkinson's disease (PD). Participants diagnosed with PD will be randomized into two intervention groups (rTMS + cervical tsMS or rTMS + thoracic tsMS) and will undergo 10 treatment sessions. Outcomes will include functional mobility, gait speed, motor function, freeing of gait, balance, quality of life, global perceived improvement and adverse events. The study is expected to identify the most effective tsMS application site to enhance mobility and motor outcomes in PD, contributing to the optimization and standardization of tsMS protocols as an adjunct therapy.",[26,27,28,29],"Parkinson's Disease (PD)","Gait Disorders","Transcranial Magnetic Stimulation","Spinal Cord Stimulation",[31,32,33,34],"gait disorders","spinal cord stimulation","transcranial magnetic stimulation","parkinson's disease","RECRUITING","2026-03-18",{"date":38,"type":39},"2026-03-23","ACTUAL",{"date":41,"type":39},"2026-01-05",{"date":43,"type":20},"2026-12",{"name":45,"class":46},"Universidade Federal de Pernambuco","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100452941","spinal-cord-stimulation-and-respiration-after-injury-100452941","NCT05178056","Spinal Cord Stimulation and Respiration After Injury","Epidural Spinal Cord Stimulation and Respiratory Motor Function After Injury","Inclusion Criteria:\n\n* At least 18 years old\n* Stable medical condition\n* Non-progressive C3-T1 AIS A-C Spinal Cord Injury (SCI)\n* Sustained SCI at least 24 months prior to entering the study\n* At least 15%-deficit in pulmonary function outcomes\n\nExclusion Criteria:\n\n* Painful musculo-skeletal dysfunction\n* Unhealed fracture\n* Contracture\n* Pressure sore\n* Urinary tract infection that might interfere with respiratory training\n* Clinically significant depression\n* Psychiatric disorders\n* Ongoing drug abuse;\n* Major cardiovascular disease\n* Major pulmonary disease\n* Ventilator dependence\n* Major endocrine disorders\n* Malignancy\n* Marked obesity\n* Deep vein thrombosis\n* HIV\u002FAIDS related illness\n* Secondary causes of respiratory dysfunction\n* Major gastrointestinal problems\n* Other major medical illness contraindicated for respiratory training\n* Pregnantcy","18 Years",{"count":19,"type":20},[23],"Respiratory motor control deficit is the leading cause of morbidity and mortality in patients with spinal cord injury. The long-term goal of this NIH-funded study is to develop a rehabilitation strategy for respiration in patients with spinal cord injury as a standard of care. Respiratory function in patients with chronic spinal cord injury can be improved by using inspiratory-expiratory pressure threshold respiratory training protocol. However, the effectiveness of this intervention is limited by the levels of functional capacity preserved below the neurological level of injury. Preliminary data obtained for this study demonstrate that electrical spinal cord stimulation applied epidurally at the lumbar level in combination with respiratory training can activate and re-organize spinal motor networks for respiration. This study is designed to investigate respiratory motor control-related responses to epidural spinal cord stimulation alone and in combination with respiratory training. By characterization of respiratory muscle activation patterns using surface electromyography in association with pulmonary functional and respiration-related cardiovascular measures, the investigators expect to determine the specific stimulation parameters needed to increase spinal excitability below level of injury to enhance responses to the input from supraspinal centers that remain after injury and to promote the neural plasticity driven by the respiratory training. This hypothesis will be tested by pursuing two Specific Aims: 1) Evaluate the acute effects of epidural spinal cord stimulation on respiratory functional and motor control properties; and 2) Evaluate the effectiveness of epidural spinal cord stimulation combined with respiratory training.",[60,29,61,62],"Spinal Cord Injuries","Breathing Exercises","Rehabilitation",[64,65],"Epidural Spinal Cord Stimulation","Respiratory Training","2026-03-11",{"date":68,"type":39},"2026-03-13",{"date":70,"type":39},"2021-12-31",{"date":72,"type":20},"2030-12-31",{"name":74,"class":46},"University of Louisville",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100493407","evoke-ecap-controlled-lead-placement-and-programming-in-chronic-pain-patients-100493407","NCT05704751","EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients","ECAP","Inclusion Criteria:\n\n1. Be 18-75 years of age or older at the time of enrolment.\n2. Symptoms of chronic predominant back pain for at least 6-months, with a minimum pain intensity of 5\u002F10 in the primary pain area on VAS pain intensity questionnaire.\n3. Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n4. Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written inform consent in English.\n5. Be willing and capable of giving informed consent.\n6. Be willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\nHave a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and\u002For confound evaluation of study endpoints, as determined by the Investigator.\n\n2\\. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n\n3\\. Subjects with chronic alcohol abuse or currently in rehabilitation. 4. Be benefitting within from an interventional procedure and\u002For surgery to treat chronic pain (Subjects should be enrolled at least 30 days from last benefit).\n\n5\\. Have prior experience with SCS. 6. Have an existing drug pump and\u002For another active implantable device such as a pacemaker.\n\n7\\. Have a condition currently requiring or likely to require the use of diathermy.\n\n8\\. Have an active systemic or local infection at the anticipated needle entry site.\n\n9\\. Be pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal).\n\n10\\. Are currently nursing (if female).\n\n11\\. Be concomitantly participating in another clinical study.","75 Years",{"count":84,"type":20},20,"OBSERVATIONAL","This study is designed to evaluate the feasibility of using intra-operative ECAP and Late-Response (LR) recordings for confirmation of activating the neuronal target of the dorsal column in a single-stage SCS lead placement procedure. The collected ECAP and LR data will be analysed post-hoc to further evaluate its utility for determining the laterality of lead placement with respect to the physiologic midline of the dorsal column.",[88,29],"Back Pain Lower Back Chronic",[90,32,91],"closed loop","chronic back pain","2026-01-07",{"date":94,"type":39},"2026-01-08",{"date":96,"type":39},"2023-10-27",{"date":98,"type":20},"2026-04-01",{"name":100,"class":46},"Barts & The London NHS Trust",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100618349","does-spinal-cord-stimulation-have-an-effect-beyond-patients-expectations-an-investigation-of-treatment-and-placebo-effects-100618349","NCT07330466","Does Spinal Cord Stimulation Have an Effect Beyond Patients' Expectations? An Investigation of Treatment and Placebo Effects","Does Spinal Cord Stimulation (SCS) Have an Effect Beyond Patients' Expectations? An Investigation of Treatment and Placebo Effects","Inclusion Criteria:\n\n* Patients (\\>18 years of age) with SCS implanted to treat chronic pain.\n* Patients who consent to participation and can cooperate in the study.\n* Use of continuous paresthesia-free SCS for minimum 6 months prior to participation in the study.\n* Pain score of 7 or less on a 0-10 scale in the most painful area treated with SCS, rated upon inclusion.\n* Patients not receiving other neuromodulation treatment.\n* Patients who have not undergone changes in their (pain relevant) medication during the last 30 days (pro necessitate medication allowed).",{"count":109,"type":20},25,[23],"The aim of the study is to evaluate treatment outcomes of Spinal Cord Stimulation. In the study each patient participates in four test sessions of 4-5 hours. Patients arrive for test days with their stimulation on. In each test session, baseline pain is first evaluated. Then, SCS is regulated (on\u002Foff) and patients evaluate their pain intensity immidiately and every 15 minutes during the test sessions. Patients are blinded to the treatment conditions during their participation in the study. At all times, patients can resume their usual treatment.",[29],[29,114],"Chronic pain","2026-01-04",{"date":117,"type":39},"2026-01-09",{"date":119,"type":39},"2024-09-01",{"date":121,"type":20},"2027-07",{"name":123,"class":46},"University of Aarhus",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":47},"100564555","application-of-thoracic-epidural-scs-for-managing-fog-in-patients-with-advanced-parkinsons-disease-100564555","NCT06630702","Application of Thoracic Epidural SCS for Managing FOG in Patients With Advanced Parkinson's Disease","Application of Thoracic Epidural Spinal Cord Stimulation (SCS) for Managing Freezing of Gait (FOG) in Patients With Advanced Parkinson's Disease","Inclusion Criteria:\n\n* Age:40-85 years old.\n* Patients with primary Parkinson\\'s disease who have been diagnosed by a movement disorder specialist for more than 5 years. Although they have a clear response to drugs, they have a frozen gait that cannot be controlled by drugs. Lower limb pain may be present with or without Parkinson\\'s non-motor symptoms.\n* No other secondary gait problems.\n\nExclusion Criteria:\n\n* Atypical Parkinson's disease.\n* Patients with spinal cord injuries.\n* Medication-controlled frozen gait.\n* It is expected that there are lesions near the implantation area causing spinal canal stenosis or myelopathy (can be ruled out by MRI).\n* It is expected that the implantation area has undergone previous surgery or there is infection near the implantation area, which may affect the success rate of implantation or increase concerns about complications (such as severe extraspinal adhesion, or spinal cord damage in previous surgeries).\n* People with abnormal coagulation function (such as hemophilia patients) or those who have been controlled by long-term use of antithrombotic drugs and cannot stop taking them in a short period of time.\n* CDR (Clinical Dementia Rating Scale) ≧2. 8. Those who are allergic to developer.","85 Years",{"count":133,"type":20},5,[23],"Spinal cord stimulation (SCS) has proven to be effective for pain that is unresponsive to medication. This technique involves an anesthesiologist or a neurosurgeon placing stimulation electrodes at the thoracic vertebrae to provide pain relief. Although SCS is not currently a standard treatment for patients with Parkinson's disease, recent studies have shown that Parkinson's patients who experience intolerable pain and undergo SCS treatment not only experience pain relief but also show improvements in gait and other Parkinson's symptoms. Therefore, the investigators aim to use temporary, minimally invasive SCS electrodes to help patients with nrFOG (non-responsive Freezing of Gait) improve their stability and reduce their risk of falls.",[137,138,29],"Parkinson Disease","Freezing of Gait",[140,137],"Spinal cord stimulation, Freezing of gait","2025-11-17",{"date":143,"type":39},"2025-11-20",{"date":145,"type":39},"2024-09-20",{"date":147,"type":20},"2027-12-31",{"name":149,"class":46},"National Taiwan University Hospital",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":47},"100553030","scs-for-patient-with-painful-diabetic-neuropathy-and-peripheral-arterial-disease-100553030","NCT06480786","SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease","Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy and Peripheral Arterial Disease: Mechanistic Insights From a Single-center, Randomized, Blinded, Sham-controlled Cross-over Proof-of-concept Trial","Inclusion Criteria:\n\n* 19 years to 89 years old\n* Diagnosed diabetes mellitus\n* Signs or symptoms of neuropathy and maximum baseline visual-analog pain scale ≥ 5 cm and peripheral arterial disease (diagnosed by ankle-brachial index \\\u003C 0.90 or vascular imaging studies) with claudication and exertion-induced visual-analog pain scale ≥ 6 cm for a minimum of 3 months\n* Successful spinal cord stimulator (SCS) trial (\\>50% relief of chronic lower extremity pain) and will have a new permanent SCS placed prior to study intervention\n\nExclusion Criteria:\n\n* Uncontrolled psychological or psychiatric disorder\n* Inability to hold antithrombotic therapy per the American Society of Regional Anesthesia guidelines\n* Non-healing wounds\n* Gangrene\n* Critical limb ischemia\n* Prior lower extremity amputation\n* Inability to adhere to study follow-up\n* Mechanical spine instability based on flexion\u002Fextension radiographs of the lumbar spine\n* Prior or current spinal cord stimulator implant","19 Years","89 Years",{"count":160,"type":20},15,[23],"Peripheral arterial disease (PAD) affects over 230 million adults worldwide and is a highly morbid, costly, and disabling condition. Ischemic leg pain drives disability in PAD patients and results from oxygen supply-demand mismatch, autonomic dysfunction, and muscle breakdown. This leg pain, which is unresponsive to traditional pharmacotherapy, limits the patient's tolerance to exercise, which is an important disease-modifying intervention. Spinal cord stimulation is a well-established therapy for medically intractable pain, including painful diabetic neuropathy (PDN) and ischemic pain, but is not part of the standard-of-care for PAD despite limited promising clinical data. Early studies used first-generation, tonic stimulation devices, but with these it was impossible to perform sham-controlled trials to test the treatment. Since then, new types of waveform treatments, including high-frequency spinal cord stimulation (SCS), have been shown to be more effective in the treatment of intractable pain. While high-frequency SCS is approved for PDN treatment, it has never been tested in the treatment of claudication pain from PAD.\n\nThis study will enroll up to 15 participants between the ages of 19 and 89 who have PAD and PDN and are successfully implanted with a permanent SCS. Twelve weeks after SCS implantation, participants will receive two weeks of stimulation and two weeks of sham intervention, in random starting order. Blood flow, blood pressure, skin oxygen levels, and participant reported pain int the lower extremities will be assessed before SCS implantation, 12 weeks after SCS implantation and during each of the treatment periods. Participants will also complete a quality of life survey at the same time points. Comparisons of these measurements with the baseline and post-implantation measurements to determine the effects of SCS.",[164,165,166,167,29,168,169],"Peripheral Arterial Disease","Painful Diabetic Neuropathy","Diabetes Mellitus, Type 2","Chronic Pain","Chronic Pain Syndrome","Limb Pain","2025-10-21",{"date":172,"type":39},"2025-10-22",{"date":174,"type":39},"2024-12-18",{"date":121,"type":20},{"name":177,"class":46},"University of Nebraska",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":133},"100459945","return-to-work-for-persistent-spinal-pain-syndrome-type-ii-patients-100459945","NCT05269212","Return to Work for Persistent Spinal Pain Syndrome Type II Patients","Objectifying Performance Assessments and Personalized Rehabilitation Trajectories to Improve Return to Work in Patients With Persistent Spinal Pain Syndrome Type II: a Randomized Controlled Trial.","OPERA","Inclusion Criteria:\n\n* Persistent Spinal Pain Syndrome Type II (PSPS-T2)\n* Chronic pain as a result of PSPS-T2 that exists for at least 6 months with a pain intensity of at least 4\u002F10 on the Numeric Rating Scale, refractory to conservative treatment.\n* Dutch speaking persons\n* Patient has been informed of the study procedures and has given written informed consent\n* Patient willing to comply with study protocol including attending the study visits\n\nExclusion Criteria:\n\n* Suffering from another chronic illness characterised by chronic generalized widespread pain (e.g. rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, scleroderma).\n* Pregnancy","60 Years",{"count":188,"type":20},112,[23],"A multicenter randomized controlled trial will be conducted to evaluate whether the ability to work in Persistent Spinal Pain Syndrome Type II (PSPS-T2) patients after SCS implantation is different after a personalized biopsychosocial rehabilitation program specifically targeting return to work (RTW) compared with usual care.",[192,29],"Failed Back Surgery Syndrome","2025-10-01",{"date":195,"type":39},"2025-10-02",{"date":197,"type":39},"2022-05-10",{"date":199,"type":20},"2027-08",{"name":201,"class":46},"Moens Maarten",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":212,"conditions":213,"keywords":220,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":47},"100595836","investigating-the-impact-of-spinal-cord-electrical-stimulation-combined-with-individualized-physical-therapy-on-lower-extremity-function-in-patients-with-spinal-cord-injury-100595836","NCT07037628","Investigating the Impact of Spinal Cord Electrical Stimulation Combined With Individualized Physical Therapy on Lower Extremity Function in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n* Aged between 20 and 70 years.\n* Diagnosed with spinal cord injury, classified as ASIA Grade A-D.\n* Neurological level of injury between T1 and L2.\n* Spinal cord injury has stabilized (for at least 3 months).\n* Currently receiving standard treatment at Hualien Tzu Chi Hospital and referred by a neurosurgeon or orthopedic surgeon to receive spinal cord stimulation (SCS) and\u002For individualized physical therapy.\n* Capable of participating in one-on-one physical therapy sessions 3 to 5 times per week, and assessed by the medical team as able to complete at least a 3 weeks course of treatment.\n* Fully conscious, able to understand the study information, and willing to sign the consent form and participate in the full assessment process.\n\nExclusion Criteria:\n\n* Individuals with severe brain injury, neurodegenerative diseases, or other major neurological disorders.\n* Those with severe fractures, joint contractures, or conditions preventing participation in lower limb training.\n* Individuals with a cardiac pacemaker or who are pregnant.\n* Those unable to comply with the treatment or assessment procedures.","20 Years","70 Years",{"count":211,"type":20},76,"This study aims to understand the differences in the effects of two rehabilitation approaches on lower limb function recovery in patients with spinal cord injuries:\n\n1. Spinal cord stimulation (SCS) combined with one-on-one physical therapy\n2. One-on-one physical therapy alone",[214,215,216,217,218,29,219],"Spinal Cord Injury","Spinal Cord Injury Thoracic","Spinal Cord Injury\u002FDamage","Spinal Cord Injury T1-L2","Spinal Cord Stimulation (SCS)","Epidural Electrical Stimulation",[221,222,223,224],"ASIA B","ASIA C","ASIA D","ASIA A","NOT_YET_RECRUITING","2025-06-24",{"date":228,"type":39},"2025-06-27",{"date":230,"type":20},"2025-08-01",{"date":232,"type":20},"2028-12-31",{"name":234,"class":46},"Lian-Cing Yan, MSPT",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":250,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":47},"100556048","evaluating-safety-and-feasibility-of-transcutaneous-spinal-cord-stimulation-following-traumatic-and-non-traumatic-spinal-cord-injury-a-pilot-study-100556048","NCT06520020","Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study","STIM","Inclusion Criteria:\n\n* Age: = 18 years and = 80 years.\n* Written informed consent by patient and\u002For legal authorized representative (LAR).\n* No other life-threatening condition.\n* No evidence of sepsis.\n* No evidence of superficial skin infection at site of surgery and intervention.\n* An established diagnosis of either:\n\n  * cervical myelopathy with modified Japanese Orthopaedic Association score of 8-14, or\n  * acute cervical \u002F thoracic SCI with ASIA Impairment Scale grade A-D (as assessed within 72 hours of injury) with neurologic level of injury (NLI) from C2 to T12.\n* The ability to undergo, or have had, surgical intervention. -. The ability to undergo transcutaneous intervention including study procedures in the posterior cervical or thoracic midline at or after 14 days from surgery.\n\nExclusion Criteria:\n\n* Any concomitant impairment of the upper and lower limb at baseline that could potentially confound the neurologic assessments; including but not limited to traumatic or disease conditions like brachial plexus injury, peripheral neuropathy, spinal hematoma, transverse myelitis, non-compressive myelopathy, dementia, and Parkinson's disease.\n* mJOA of \\>= 15 and \\\u003C= 7, or AIS grade E tSCI at baseline assessment.\n* Currently involved in another non-observational ntSCI or tSCI study, or receiving another interventional drug, that could interfere with recordings and confound adverse events.\n* Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation, at discretion of the treating surgeon and\u002For principal investigator.\n* Unable to commit to the follow-up schedule.\n* Recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study.\n* Any condition likely to result in the patient's death within the next 12 months.\n* Prisoner.\n* Pregnancy.\n* Cardiac pacemaker dependent, unable to undergo electrical stimulation.\n* Brain implant, skull prosthesis, plate and screws limiting transcranial stimulation.\n* Tattoo at site of skin electrode that causes heat\u002Fpain during stimulation.\n* Subjects who in the opinion of the investigator are not suitable for inclusion in the study, with reason documented.","80 Years",{"count":19,"type":20},[23],"The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups:\n\n1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention.\n2. Early tSCI screened during the hospital admission when cervical\u002Fthoracic spinal injury was diagnosed.\n3. Delayed tSCI (control) screened 6-24 months after acute cervical\u002Fthoracic spinal injury.",[29,247,248,249],"Electric Stimulation Therapy","Traumatic Spinal Cord Injury","Cervical Myelopathy",[251,252,253,254,255],"Stimulation","Transcutaneous","MagStim","Transcranial","Magnetic","2025-06-05",{"date":258,"type":39},"2025-06-06",{"date":260,"type":39},"2024-10-23",{"date":262,"type":20},"2026-06-30",{"name":264,"class":46},"Francis Farhadi",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100558073","spinal-cord-stimulation-for-intractable-mononeuropathy-100558073","NCT06546371","Spinal Cord Stimulation for Intractable Mononeuropathy","Spinal Cord Stimulation for Intractable Mononeuropathy: a Pilot Study","SCIMONO","Inclusion Criteria:\n\n* Suffering from painful intractable peripheral mononeuropathy in the distal extremities, preferably post-traumatic or post-surgical, confirmed by electromyography (EMG)\n* Symptoms refractory to conventional medical management for at least 6 months according to treating physician\n* 18 years or older\n* Pain score on numeric rating scale (NRS) of at least 5 (average pain intensity in week prior to assessment)\n* Stable or absent concomitant analgesics\n\nExclusion Criteria:\n\n* Mononeuropathy located in the head or torso\n* Mononeuropathy by avulsion at the plexus brachialis\n* Life expectancy \\\u003C1 year\n* Anticoagulant drug therapy or disturbed coagulation\n* Immune-compromised patients\n* Pregnancy\n* Lack of cooperation of the patient or patient has a history of noncompliance with regard to (a) medical regime(s)\n* Patients with psychological factors or addiction that require treatment",{"count":274,"type":20},12,[23],"Rationale: For patients with mononeuropathy, literature has shown that spinal cord stimulation (SCS) is an effective therapy for patients who are therapy-resistant to more conventional treatments. However, there is a strong need for higher quality evidence to determine the place of this therapy in this target group. Before conducting a large randomized controlled trial (RCT) we propose to conduct an explorative pilot study based on which an effect size estimation and power calculation for a larger study can be done. We will assess the effects of SCS in patients with mononeuropathy measured according to the \"Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials\" (IMMPACT) guidelines, and assess the stimulation paradigm preferences in these patients.\n\nObjective: To perform an explorative pilot study based on which an effect size estimation and power calculation for an efficacy trial can be done.\n\nStudy design: Mono-center explorative pilot study in 12 patients with intractable peripheral mononeuropathic pain who receive a spinal cord stimulator at the Erasmus Medical Centre.\n\nStudy population: 12 patients suffering from intractable peripheral mononeuropathic pain.\n\nIntervention: Participants who receive a spinal cord stimulator must fill in IMMPACT guideline questionnaires and undergo several measurement procedures after receiving SCS implantation. The effect of various SCS paradigms on the chronic mononeuropathic pain is assessed at 3 and 6 months.\n\nMain study parameters\u002Fendpoints: Effect of 6 months of individually optimized SCS in patients with mononeuropathy according to the IMMPACT guidelines.",[278,29],"Mononeuropathies","2025-02-27",{"date":281,"type":39},"2025-03-03",{"date":283,"type":39},"2024-05-13",{"date":285,"type":20},"2025-05",{"name":287,"class":46},"Erasmus Medical Center",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100555672","efficacy-and-safety-of-spinal-cord-stimulation-in-patients-with-spinal-cord-stimulation-100555672","NCT06515132","Efficacy and Safety of Spinal Cord Stimulation in Patients With Spinal Cord Stimulation","Efficacy and Safety of Spinal Cord Stimulation in Patients With Disorders of Consciousness: A Multicenter, Double-blind, Randomized Controlled Trail","SCORS-DOC","Inclusion Criteria:\n\n* Male and female patients between the ages of 18 and 65, experiencing DOC for a duration ranging from 3 months to 1 year following brain disease.\n* Patients diagnosed with DOC as a consequence of traumatic brain injury, hypertensive intracerebral hemorrhage, or severe cerebral infarction.\n* Patients exhibiting stable cerebral anatomy and no need for further cranioplasty or hydrocephalus shunt.\n* Patients in MCS, who fulfill at least one of the following criteria: ① Demonstrating an oriented response to noxious stimuli; ② Exhibiting sustained eye tracking behavior; ③ Displaying purposeful movements; ④ Manifesting comprehension of language or emotions and actions (often observed in specific environments such as when hearing family members crying).\n* The vital signs and state of consciousness are stable: normal body temperature, the spontaneous breathing is stable (minimal sputum production and respiratory stability without oxygen supplementation for at least 2 hours); there is no significant change in the level of consciousness for at least 1 month and more.\n* Presence of short-latency responses (N20\u002FP25) on somatosensory evoked potentials (SEP) recorded from the median nerve in the upper limbs.\n* Written informed consent obtained from legal guardians or representatives.\n\nExclusion Criteria:\n\n* Patients with a history of severe neurological or psychiatric disorders, or other significant diseases impacting prognosis prior to the onset of DOC;\n* Patients with contraindications for surgery, such as acute infections or coagulation disorders;\n* Patients who require short-wave diathermy treatment and are unable to undergo neurostimulation;\n* Patients with hypoxic brain injury due to suffocation, cardiac arrest, or respiratory arrest;\n* Patients with brainstem hemorrhage;\n* Pregnant women;\n* Patients who voluntarily request SCS implantation but are unwilling to cooperate with the research protocol;\n* Participants in other clinical trials.","65 Years",{"count":298,"type":20},50,[23],"Investigating the efficacy and safety of spinal cord stimulation for patients with disorders of consciousness.",[302,29],"Disorder of Consciousness",[302,29,304],"Randomized clinical trail","2025-01-04",{"date":307,"type":39},"2025-01-07",{"date":309,"type":20},"2025-01-10",{"date":311,"type":20},"2026-05-30",{"name":313,"class":46},"Huashan Hospital",3,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":21,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":47},"100516136","safety-feasibility-and-efficacy-of-tscs-on-stabilizing-blood-pressure-for-acute-inpatients-with-sci-100516136","NCT06000592","Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI","Safety, Feasibility, and Efficacy of Transcutaneous Spinal Cord Stimulation on Stabilizing Blood Pressure for Acute Inpatients With Spinal Cord Injury","Inclusion Criteria:\n\n* Newly injured patients with traumatic SCI\n* Admitted to Acute Inpatient Rehabilitation at Mount Sinai\n* Within one year of SCI\n* Seated hypotension (systolic BP ≤ 110 mmHg for males or ≤ 100 mmHg for females)\n* Orthostatic hypotension (fall in systolic BP ≥ 20 mmHg and\u002For a fall in diastolic BP ≥ 10 mmHg within 10 minutes of assuming an upright position)\n* Daily fluctuation in systolic BP ≥ 20 mmHg and\u002For fluctuation in diastolic BP ≥ 10 mmHg\n* At least 14 years old\n\nExclusion Criteria:\n\n* Implanted brain\u002Fspine\u002Fnerve stimulators\n* Cochlear implants\n* Cardiac pacemaker\u002Fdefibrillator, or intracardiac lines\n* Open skin lesions on or near the electrode placement sites (neck, upper back)\n* Significant coronary artery or cardiac conduction disease\n* Recent history of myocardial infarction\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician","14 Years","100 Years",{"count":298,"type":20},[23],"Current forms of pharmacologic and non-pharmacologic treatments for hypotension and orthostatic hypotension (OH) remain inadequate during acute inpatient rehabilitation (AIR) following a traumatic spinal cord injury (SCI). A critical need exists for the identification of safe, practical, and effective treatment options that stabilize blood pressure (BP) after traumatic SCI. Recent published evidence suggests that transcutaneous Spinal Cord Stimulation (TSCS) can be used to raise seated BP, and mitigate the falls in BP during orthostatic repositioning in individuals with chronic SCI. This site-specific project will focus on the use of TSCS to stabilizing seated BP and mitigate the fall in BP during orthostatic repositioning during AIR following traumatic SCI.",[328,60,329,248,29,330,331,332],"Acute Spinal Cord Injury","Neuromodulation","SCI - Spinal Cord Injury","Blood Pressure","Blood Pressure Disorders","2024-04-01",{"date":335,"type":39},"2024-04-02",{"date":337,"type":39},"2022-01-01",{"date":339,"type":20},"2026-10-01",{"name":341,"class":342},"Jill M. Wecht, Ed.D.","FED",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":21,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":314},"100505455","pain-medication-tapering-for-patients-with-persistent-spinal-pain-syndrome-type-2-treated-with-spinal-cord-stimulation-100505455","NCT05861609","Pain Medication Tapering for Patients With Persistent Spinal Pain Syndrome Type 2, Treated With Spinal Cord Stimulation.","PIANISSIMO","Inclusion Criteria:\n\n* Patients with PSPS T2, defined as patients suffering from neuropathic pain of radicular origin with pain in the lower back and\u002For leg(s), of an intensity of at least 4\u002F10 on the Numeric Rating Scale, for a period of at least 6 months after a minimum of one anatomically successful spinal surgery and being refractory to conservative treatment (according to Belgian reimbursement rules from January 1st, 2018)\n* Patients need to be scheduled for SCS to be eligible for participation in the study\n* Currently taking opioids\n* 18 years and older\n* Speaking and reading Dutch or French\n\nExclusion Criteria:\n\n* Being actively treated for cancer.\n* Having a life expectancy below 6 months.\n* Receiving intrathecal drug delivery.\n* Patients with contraindications for Clonidine (e.g., known hypotension which requires medication) or for Buprenorphine\u002FNaloxone (e.g., severe respiratory insufficiency, hepatic insufficiency).\n* Epilepsy treated by Pregabalin.\n* Currently using benzodiazepines at more than 40 mg diazepam-equivalents per day.",{"count":351,"type":20},195,[23],"The primary objective of the study is to examine whether there is a difference in disability after 12 months of Spinal Cord Stimulation (SCS) in patients with Persistent Spinal Pain Syndrome Type 2 (PSPS T2) after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation. The secondary objective of the study is to examine whether there is a difference after 12 months of SCS in PSPS T2 patients after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation on pain intensity, health-related quality of life, participation, domains affected by substance use, anxiety and depression, medication use, psychological constructs, sleep, central sensitization, and healthcare expenditure.",[355,29],"Persistent Spinal Pain Syndrome Type 2","2023-10-17",{"date":358,"type":39},"2023-10-18",{"date":360,"type":39},"2023-09-29",{"date":362,"type":20},"2026-09",{"name":201,"class":46}]